BioWorld

Dec. 11, 2009

Cytokinetics Is All Muscle: Ends Cancer Deal with GSK

A year after GlaxoSmithKline plc backed away from two cancer drugs covered under its collaboration with Cytokinetics Inc., the big pharma handed back rights to the third and final compound as well. (BioWorld Today) Read More

New Trial a Show of Confidence for Oncothyreon Cancer Vaccine

Plaques, Bad Cholesterol Get Partial Rehab in Alzheimer's

Despite Concerns, Panel Backs Gilead Inhaled Aztreonam in CF

Financings Roundup

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...